Merck & Co Inc (MRK)

MRK on New York Consolidated

57.60USD
24 Apr 2015
Change (% chg)

$0.09 (+0.16%)
Prev Close
$57.51
Open
$57.85
Day's High
$58.19
Day's Low
$57.51
Volume
7,866,496
Avg. Vol
11,040,636
52-wk High
$63.62
52-wk Low
$52.49

MRK

Chart for MRK

About

Merck & Co., Inc., is a health care company. The Company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $162,918.91
Shares Outstanding(Mil.): 2,828.45
Dividend: 0.45
Yield (%): 3.12

Financials

  MRK Industry Sector
P/E (TTM): 14.06 41.06 41.71
EPS (TTM): 4.10 -- --
ROI: 14.50 16.86 16.20
ROE: 24.22 17.36 17.00
Search Stocks

Merck oral hepatitis C regimen shows 95 pct cure rate

April 24 - Merck and Co Inc presented trial results on Friday showing that a once-daily combination of two experimental pills cured 95 percent of previously untreated hepatitis C patients after 12 weeks.

24 Apr 2015

Merck's Keytruda shrinks lung cancer tumors, FDA approval sought

- Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.

19 Apr 2015

CORRECTED-Merck's Keytruda shrinks lung cancer tumors, FDA approval sought

April 19 - Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.

19 Apr 2015

Merck files for FDA approval of Keytruda in lung cancer

- Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease.

19 Apr 2015

Merck files for FDA approval of Keytruda in lung cancer

April 19 - Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease.

19 Apr 2015

Merck aims to quickly repay up to $5 billion in loans: CFO in Boersen-Zeitung

FRANKFURT - Germany's Merck aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich , its finance chief told daily Boersen-Zeitung.

18 Apr 2015

Merck aims to quickly repay up to $5 bln in loans -CFO in Boersen-Zeitung

FRANKFURT, April 18 - Germany's Merck aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich, its finance chief told daily Boersen-Zeitung.

18 Apr 2015

Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable

(The following statement was released by the rating agency) CHICAGO, April 13 (Fitch) Fitch Ratings has downgraded Merck & Co.'s (Merck) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook to Stable from Negative. In addition, the company's short-term IDR has been affirmed at 'F1'. Merck had $21.7 billion in outstanding debt at Dec. 31, 2014. A full list of Fitch's ratings actions follows at the end of this release. KEY RATING DRIVERS --Fitch expects MRK

13 Apr 2015

Merck KGaA's deputy chief Oschmann set to become CEO: Manager Magazin

FRANKFURT - Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.

20 Mar 2015

Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin

FRANKFURT, March 20 - Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.

20 Mar 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks